Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1042 Monotherapy and Combination Therapy in Japanese Subjects With Malignant Solid Tumors
NCT06057038Phase 1Active, not recruiting
- Sponsor
- Genmab
- Start
- Nov 2023
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tecaginlimab in malignant solid tumor, head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) (5 arms), sponsored by Genmab. Primary endpoints: Dose Limiting Toxicities at 21 days and Adverse Events up to 3 years. Started Nov 2023; status: active, not recruiting.
02
Drugs
tecaginlimab
03
Conditions
malignant solid tumorhead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06057038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057038.